spacer
home > epc > autumn 2018 > quality compliance
PUBLICATIONS
European Pharmaceutical Contractor

Quality Compliance

Clinical and manufacturing departments tend to view quality and compliance from different perspectives because they are each focussed on different sets of compliance requirements (or perhaps the industry has become conditioned to seeing them as distinct on a perfunctory level). However, both groups can streamline compliance and increase effectiveness by applying many of the same quality practices to their compliance efforts. The core ideologies that form the basis of quality best practices are universal principles that apply not only to Good Manufacturing Practice (GMP) but to Good Clinical Practice (GCP) as well.

Intersections in Compliance Requirements

Clinical and manufacturing compliance efforts overlap in several comparable areas:

Deviations
Just as deviations in manufacturing are indicative of poor product quality, the lack of protocol adherence and inconsistencies in protocol implementation are signifiers of quality deficiencies in clinical trials. Since the study protocol is the single most important document in a clinical trial, adherence to the protocol is essential if quality is to be maintained. Correspondingly, strict observance of production standard operating procedures (SOPs) in manufacturing is critical to effective quality management. Parallel to an effective quality management system’s (QMS) criticality to deviation management in manufacturing, a systematised approach to clinical quality that emphasises clinical quality management principles can refine the focus on events that occur across studies and product lines and help manage actiontaking once a deviation issue has been identified. Always keep in mind that many deviation management principles can be applied in both manufacturing and clinical scenarios, such as identifying the source of an issue, identifying any areas that may be impacted, and using universal problemsolving techniques to conduct root cause analyses (ie, fishbone diagrams, the ‘5 Whys’ technique, etc).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patricia Santos-Serrao, MasterControl’s Director of Clinical and Regulatory Solutions, started her life sciences career in 1994 with Schering-Plough and later joined Boehringer Ingelheim Pharmaceutical. Within both organisations, Patricia took a leading role in transitioning business processes, document management, and submission compilation from paper to electronic systems. She is a member of Regulatory Affairs Professional Society (RAPS) and earned her Regulatory Affairs Certification from RAPS and the Regulatory Affairs Certification Board. Patricia is a member of the Drug Information Association (DIA) and a member of the DIA-sponsored Trial Master File Reference Model working group.
spacer
Patricia Santos-Serrao
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services expands analytical Service Spectrum in Biosimilar Development Support

Heilbronn/Dortmund February 2019: The success or failure of the development of a biopharmaceutical product is also governed by protein stability. Protein stability is considered a critical parameter during manufacturing, production, formulation, long term storage, efficacy, and delivery to patients. To meet our customer demands now and in the future, PPS always invests in new analytical technique and recently added a new Differential Scanning Calorimetry (DSC) device.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement